Maya Khalil
University of Alabama at Birmingham · 29 works · 1,671 citations · h-index 6
Top works
- Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
- Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
- NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024
- Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
- SWOG S2302, PRAGMATICA-LUNG: A pragmatic trial designed to increase participant representation.
- Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma
- Concordance between Immunohistochemistry and Microarray Gene Expression Profiling for Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Statuses in Breast Cancer Patients in Lebanon
- NCCN Guidelines® Insights: Small Cell Lung Cancer, Version 2.2026
- The tumor microenvironment in EGFR-driven loco-regional lung adenocarcinoma can predict higher risk of recurrence.
- Phase I dose-escalation and cohort expansion study of the anti-BTLA antibody, tifcemalimab, in combination with toripalimab (anti-PD-1) in heavily pretreated patients (pts) with advanced malignancies.
- First-line cytotoxic chemotherapy regimen for non-small cell lung cancer in the elderly population: plus ca change
- A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors
- Exploring the potential of combination immune checkpoint strategies in non-small cell lung cancer (NSCLC).
- Malignancies in immune deficiencies
- Association of ALOX12B gene alterations with TMB and immune checkpoint inhibitor (ICI) outcomes.
- Additional file 1: of Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
- Navigating the clinical trial maze: Identifying barriers to enrollment among patients with advanced cancer in a community-academic partnership.
- HSR25-148: The State of Lung Cancer in Alabama
- Building a community-academic partnership to improve clinical trial access in southern Alabama.
- Enhancing diverse representation in clinical studies: Recommendations from external subject matter experts (SMEs) and patients to optimize protocols, informed consent and study designs.